New horizons for host defense peptides and lantibiotics.

[1]  J. Wehkamp,et al.  Innate immune dysfunction in inflammatory bowel disease , 2012, Journal of internal medicine.

[2]  Erinna F. Lee,et al.  Evaluation of diverse α/β-backbone patterns for functional α-helix mimicry: analogues of the Bim BH3 domain. , 2012, Journal of the American Chemical Society.

[3]  H. Kristensen,et al.  Efficacy of NZ2114, a Novel Plectasin-Derived Cationic Antimicrobial Peptide Antibiotic, in Experimental Endocarditis Due to Methicillin-Resistant Staphylococcus aureus , 2011, Antimicrobial Agents and Chemotherapy.

[4]  J. Vederas,et al.  Solid supported chemical syntheses of both components of the lantibiotic lacticin 3147. , 2011, Journal of the American Chemical Society.

[5]  W. DeGrado,et al.  Antibacterial Mechanism of Action of Arylamide Foldamers , 2011, Antimicrobial Agents and Chemotherapy.

[6]  D. O'sullivan,et al.  Transcription Analysis of a Lantibiotic Gene Cluster from Bifidobacterium longum DJO10A , 2011, Applied and Environmental Microbiology.

[7]  Robert E. W. Hancock,et al.  Multifunctional cationic host defence peptides and their clinical applications , 2011, Cellular and Molecular Life Sciences.

[8]  S. Donadio,et al.  Efficacy of the New Lantibiotic NAI-107 in Experimental Infections Induced by Multidrug-Resistant Gram-Positive Pathogens , 2011, Antimicrobial Agents and Chemotherapy.

[9]  J. Hillman,et al.  Human serum binding and its effect on the pharmacodynamics of the lantibiotic MU1140. , 2010, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[10]  G. Diamond,et al.  Activity of antimicrobial peptide mimetics in the oral cavity: II. Activity against periopathogenic biofilms and anti-inflammatory activity. , 2010, Molecular oral microbiology.

[11]  C. Hill,et al.  The dawning of a ‘Golden era’ in lantibiotic bioengineering , 2010, Molecular microbiology.

[12]  A. Mor,et al.  Mechanisms Mediating Bactericidal Properties and Conditions That Enhance the Potency of a Broad-Spectrum Oligo-Acyl-Lysyl , 2010, Antimicrobial Agents and Chemotherapy.

[13]  A. Ivankin,et al.  A miniature mimic of host defense peptides with systemic antibacterial efficacy , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[14]  J. Hillman,et al.  Pharmacokinetic and pharmacodynamic evaluation of the lantibiotic MU1140. , 2010, Journal of pharmaceutical sciences.

[15]  P. Nibbering,et al.  The human lactoferrin-derived peptide hLF1-11 primes monocytes for an enhanced TLR-mediated immune response , 2010, BioMetals.

[16]  GREGORY N. TEW,et al.  De novo design of antimicrobial polymers, foldamers, and small molecules: from discovery to practical applications. , 2010, Accounts of chemical research.

[17]  Guy Duportail,et al.  Consequences of isostructural main-chain modifications for the design of antimicrobial foldamers: helical mimics of host-defense peptides based on a heterogeneous amide/urea backbone. , 2010, Angewandte Chemie.

[18]  P. Nibbering,et al.  Antimicrobial Peptide hLF1-11 Directs Granulocyte-Macrophage Colony-Stimulating Factor-Driven Monocyte Differentiation toward Macrophages with Enhanced Recognition and Clearance of Pathogens , 2009, Antimicrobial Agents and Chemotherapy.

[19]  J. Donnelly,et al.  Safety and tolerability of the antimicrobial peptide human lactoferrin 1-11 (hLF1-11) , 2009, BMC medicine.

[20]  L. Foster,et al.  Intracellular Receptor for Human Host Defense Peptide LL-37 in Monocytes1 , 2009, The Journal of Immunology.

[21]  H. Kristensen,et al.  In Vivo Pharmacodynamic Characterization of a Novel Plectasin Antibiotic, NZ2114, in a Murine Infection Model , 2009, Antimicrobial Agents and Chemotherapy.

[22]  W. DeGrado,et al.  De novo design and in vivo activity of conformationally restrained antimicrobial arylamide foldamers , 2009, Proceedings of the National Academy of Sciences.

[23]  J. Reunanen,et al.  Survival of nisin activity in intestinal environment , 2009, Biotechnology Letters.

[24]  R. P. Ross,et al.  Discovery of medically significant lantibiotics. , 2009, Current drug discovery technologies.

[25]  D. Sturdevant,et al.  The antimicrobial peptide‐sensing system aps of Staphylococcus aureus , 2007, Molecular microbiology.

[26]  Emile de Heer,et al.  Human lactoferrin-derived peptide's antifungal activities against disseminated Candida albicans infection. , 2007, The Journal of infectious diseases.

[27]  P. B. Lynch,et al.  Fate of the Two-Component Lantibiotic Lacticin 3147 in the Gastrointestinal Tract , 2007, Applied and Environmental Microbiology.

[28]  C. Hill,et al.  Antimicrobial activity of lacticin 3,147 against clinical Clostridium difficile strains. , 2007, Journal of medical microbiology.

[29]  Oreola Donini,et al.  An anti-infective peptide that selectively modulates the innate immune response , 2007, Nature Biotechnology.

[30]  G. Wong,et al.  Synthetic antimicrobial oligomers induce a composition-dependent topological transition in membranes. , 2007, Journal of the American Chemical Society.

[31]  K. Sayama,et al.  Antimicrobial peptides human beta-defensins stimulate epidermal keratinocyte migration, proliferation and production of proinflammatory cytokines and chemokines. , 2007, The Journal of investigative dermatology.

[32]  R. Hancock,et al.  Cationic host defence peptides: Innate immune regulatory peptides as a novel approach for treating infections , 2007, Cellular and Molecular Life Sciences.

[33]  D. Sturdevant,et al.  The human anionic antimicrobial peptide dermcidin induces proteolytic defence mechanisms in staphylococci , 2007, Molecular microbiology.

[34]  G. Tew,et al.  Antimicrobial activity of an abiotic host defense peptide mimic. , 2006, Biochimica et biophysica acta.

[35]  S. Fournel,et al.  Mimicking helical antibacterial peptides with nonpeptidic folding oligomers. , 2006, Chemistry & biology.

[36]  J. J. Grote,et al.  Development of novel LL-37 derived antimicrobial peptides with LPS and LTA neutralizing and antimicrobial activities for therapeutic application , 2006, Peptides.

[37]  R. J. Doerksen,et al.  Biomimetic facially amphiphilic antibacterial oligomers with conformationally stiff backbones. , 2006, Chemistry & biology.

[38]  M. Lavoie,et al.  In vivo activity of mutacin B-Ny266. , 2005, The Journal of antimicrobial chemotherapy.

[39]  K. Brogden.  Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? , 2005, Nature Reviews Microbiology.

[40]  L. Dijkshoorn,et al.  The Synthetic N-Terminal Peptide of Human Lactoferrin, hLF(1-11), Is Highly Effective against Experimental Infection Caused by Multidrug-Resistant Acinetobacter baumannii , 2004, Antimicrobial Agents and Chemotherapy.

[41]  Niv Papo,et al.  In Vitro Activity and Potency of an Intravenously Injected Antimicrobial Peptide and Its dl Amino Acid Analog in Mice Infected with Bacteria , 2004, Antimicrobial Agents and Chemotherapy.

[42]  Liandong Huan,et al.  Site-directed mutagenesis of the hinge region of nisinZ and properties of nisinZ mutants , 2004, Applied Microbiology and Biotechnology.

[43]  R. J. Doerksen,et al.  Nontoxic membrane-active antimicrobial arylamide oligomers. , 2004, Angewandte Chemie.

[44]  D. Deleu,et al.  Red man syndrome , 2002, Critical care.

[45]  L. Kwak,et al.  Mammalian defensins in immunity: more than just microbicidal. , 2002, Trends in immunology.

[46]  M. Zasloff.  Antimicrobial peptides of multicellular organisms , 2002, Nature.

[47]  W. DeGrado,et al.  De Novo Design, Synthesis, and Characterization of Antimicrobial β-Peptides , 2001 .

[48]  R. Novick,et al.  Activity of nisin against Streptococcus pneumoniae, in vitro, and in a mouse infection model. , 1998, The Journal of antimicrobial chemotherapy.

[49]  G. Seibert,et al.  Mersacidin, a new antibiotic from Bacillus. In vitro and in vivo antibacterial activity. , 1992, The Journal of antibiotics.

[50]  A. Malabarba,et al.  Synthesis and biological activity of some amide derivatives of the lantibiotic actagardine. , 1990, The Journal of antibiotics.

[51]  B. Cavalleri,et al.  Physico-chemical and biological properties of actagardine and some acid hydrolysis products. , 1985, The Journal of antibiotics.

[52]  R. Falconer,et al.  Nisin in experimental tuberculosis. , 1952, Lancet.

[53]  A. Barron,et al.  Progress in the de novo design of structured peptoid protein mimics. , 2011, Biopolymers.

[54]  J. Gunn,et al.  Salmonella-regulated lipopolysaccharide modifications. , 2010, Sub-cellular biochemistry.

[55]  H. Derendorf,et al.  Pharmacodynamic activity of the lantibiotic MU1140. , 2009, International journal of antimicrobial agents.

[56]  H. Giamarellou,et al.  Multidrug-Resistant Gram-Negative Infections are the Treatment Options? , 2009 .

[57]  J. Rutter,et al.  Power2: The power of yeast genetics applied to the powerhouse of the cell , 2015, Trends in Endocrinology & Metabolism.